ARDX - ア―デリックス (Ardelyx Inc.) ア―デリックス

 ARDXのチャート


 ARDXの企業情報

symbol ARDx
会社名 Ardelyx Inc (ア―デリックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アーデリックス(Ardelyx Inc.)は臨床段階のバイオ医薬品会社である。同社の治療法は心臓麻痺及び胃腸(GI)疾患の治療に重点を置く。同社はバイオ医薬品の研究、開発と商品化事業を通じて事業を運営する。同社の製品ラインには、心臓血管系ポートフォリオと胃腸ポートフォリオを含む。同社の心臓血管系ポートフォリオは慢性腎疾患(CKD)と心不全患者にある高カリウム血症の治療向け第III相臨床開発中のRDX7675及び透析末期腎疾患(ESRD)患者にある高リン酸血症治療向け第III相臨床開発中のtenapanorという2つの第III相臨床製品候補を含む。心臓血管系ポートフォリオには、tenapanor、RDX7675、RDX013及びRDX011を含む。胃腸ポートフォリオは便秘を伴う過敏性腸症候群(IBS-C)の治療のために、tenapanorによって導かれる。胃腸ポートフォリオには、tenapanor、RDX8940、RDX011及びRDX023が含まれる。   ア―デリックスは米国の臨床段階のバイオ医薬品企業。GIおよび代謝性疾患の治療ための胃腸管で排他的に動作する小分子治療薬の発見、開発、商業化に焦点を当てている。製品候補のTenapanorは、胃腸管におけるナトリウムのトランスポ―タ―の阻害剤投与小分子の経口剤。   
本社所在地 34175 Ardenwood Boulevard Suite 200 Fremont CA 94555 USA
代表者氏名 David M. Mott デビッド・モット
代表者役職名 Independent Chairman of the Board
電話番号 +1 510-745-7047
設立年月日 39356
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 75人
url www.ardelyx.com
nasdaq_url https://www.nasdaq.com/symbol/ardx
adr_tso
EBITDA EBITDA(百万ドル) -47.36200
終値(lastsale) 3.96
時価総額(marketcap) 245732853.96
時価総額 時価総額(百万ドル) 248.21500
売上高 売上高(百万ドル) 44.35000
企業価値(EV) 企業価値(EV)(百万ドル) 84.32000
当期純利益 当期純利益(百万ドル) -49.92000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Ardelyx Inc revenues increased from $0K to $2.4M. Net loss decreased 27% to $39.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development - other decrease of 32% to $27.5M (expense) Stock-based Compensation in Research and decrease of 23% to $1.9M (expense).

 ARDXのテクニカル分析


 ARDXのニュース

   Ardelyx to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference  2020/11/23 13:00:00 PR Newswire
FREMONT, Calif., Nov. 23, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that a webcast of Mike Raab,…
   Ardelyx to Webcast Virtual Analyst Day  2020/11/06 13:00:00 PR Newswire
FREMONT, Calif., Nov. 6, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that it will hold a virtual Analyst Day on…
   Ardelyx Reports Third Quarter 2020 Financial Results and Business Highlights  2020/11/05 13:00:00 PR Newswire
FREMONT, Calif., Nov. 5, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today reported business highlights and…
   Ardelyx Is it time to Buy before this week’s earning report Stock market Insights & financial analysis  2020/11/04 18:57:00 Stock Market Daily
Ardelyx announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Irritable Bowel Syndrome Treatment Market 2020 Research and Developments Abbott Laboratories, Allergan plc, Ardelyx Inc|MGI  2020/11/02 02:49:11 OpenPR
Irritable bowel syndrome is a gastrointestinal disorder of gut that may be identified by colon muscle contraction. It majorly affects the large intestine. In addition, it is associated with the malfunction of the bowel, and majorly occurs in geriatric population.
   Why This FDA Win for Ardelyx Is Definitely a ‘Sell the News’ Moment  2020/09/15 14:20:33 24/7 Wall street
   Ardelyx Announces FDA Acceptance for Filing of its New Drug Application of Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis  2020/09/15 12:00:00 PR Newswire
FREMONT, Calif., Sept. 15, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that the U.S. Food and Drug Administration…
   Ardelyx to Participate in Three Upcoming Investor Conferences in September  2020/09/08 12:00:00 PR Newswire
FREMONT, Calif., Sept. 8, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that Ardelyx management will participate in…
   Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights  2020/08/06 12:00:00 PR Newswire
FREMONT, Calif., Aug. 6, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today reported business highlights and…
   Ardelyx Selected as a Finalist in the Fierce Innovation Awards for the Development of its First-in-Class Product Candidate Tenapanor  2020/08/03 12:00:00 PR Newswire
FREMONT, Calif., Aug. 3, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that tenapanor has been…
   Ardelyx to Present at the Cowen and Company 40th Annual Health Care Conference  2020/02/26 13:00:00 PR Newswire
FREMONT, Calif, Feb. 26, 2020 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present at the Cowen and Company 40th Annual Health Care Conference at 8:00 a.m. ET on Wednesday, March 4, 2020 in Boston, MA….
   Ardelyx to Present at the 9th Annual SVB Leerink Global Healthcare Conference  2020/02/19 13:00:00 PR Newswire
FREMONT, Calif., Feb. 19, 2020 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present at the 9th Annual SVB Leerink Global Healthcare Conference at 3:30 p.m. ET on Wednesday, Feb. 26, 2020 in New York…
   The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering  2019/12/20 13:12:05 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 19.) Acceleron Pharma Inc (NASDAQ: XLRN ) Ardelyx Inc (NASDAQ: ARDX ) AstraZeneca plc (NYSE: AZN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) (priced its 2-million-share common stock offering at $87 per share) Clearside Biomedical Inc (NASDAQ: CLSD ) Cortexyme Inc (NASDAQ: CRTX ) Cue Biopharma Inc (NASDAQ: CUE ) Exagen Inc (NASDAQ: XGN ) Globus Medical Inc (NYSE: GMED ) Horizon Therapeutics PLC (NASDAQ: HZNP ) HEALTH SCIENCES/SH (NASDAQ: IMVT ) (The acquisition vehicle announced merger with Immuvant, a clinical-stage biopharma company focusing on autoimmune disorders) IVERIC bio Inc (NASDAQ: ISEE ) Johnson & Johnson (NYSE: JNJ ) (Barclays upgraded shares to Overweight) The Medicines Company (NASDAQ: MDCO ) Merck & Co., Inc. (NYSE: MRK ) Mirum Pharmaceuticals Inc (NASDAQ: MIRM ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Monopar Therapeutics Inc. (NASDAQ: MNPR ) (Went public Thursday) Myokardia Inc (NASDAQ: MYOK ) NeoGenomics, Inc. (NASDAQ: NEO ) Novan Inc (NASDAQ: NOVN ) Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP ) Principia Biopharma Inc (NASDAQ: PRNB ) Quest Diagnostics Inc (NYSE: DGX ) Recro Pharma Inc (NASDAQ: REPH ) Sanofi SA (NASDAQ: SNY ) SpringWorks Therapeutics Inc (NASDAQ: SWTX ) Down In The Dumps (Biotech stocks that hit 52-week lows Dec. 19.) Aethlon Medical, Inc. (NASDAQ: AEMD ) Anixa Biosciences Inc (NASDAQ: ANIX ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Correvio Pharma Corp (NASDAQ: …
   Ardelyx : Announces Pricing of Upsized Public Offering of Common Stock | MarketScreener  2019/12/05 04:33:03 MarketScreener
FREMONT, Calif., Dec. 4, 2019 /PRNewswire/ -- Ardelyx, Inc. , a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people… | December 5, 2019
   Ardelyx Announces Pricing of Upsized Public Offering of Common Stock  2019/12/05 04:32:00 PR Newswire
FREMONT, Calif., Dec. 4, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced the pricing of an underwritten public…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ア―デリックス ARDX Ardelyx Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)